Genomes and Genes
Gene Symbol: TET2
Description: tet methylcytosine dioxygenase 2
Alias: KIAA1546, MDS, methylcytosine dioxygenase TET2, tet oncogene family member 2
Publications175 found, 100 shown here
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesOmar Abdel-Wahab
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 114:144-7. 2009..Based on the recent identification of TET2 mutations, we evaluated the mutational status of TET1, TET2, and TET3 in myeloproliferative neoplasms (MPNs), ..
- Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remissionOlivier Nibourel
Laboratoire d Hematologie, Centre Hospitalier Regional Universitaire de Lille, Boulevard du Professeur Leclercq, Lille Cedex, France
Blood 116:1132-5. 2010Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms...
- TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23)R B Lorsbach
Leukemia 17:637-41. 2003
- TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosisA Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 23:905-11. 2009High-throughput DNA sequence analysis was used to screen for TET2 mutations in bone marrow-derived DNA from 239 patients with BCR-ABL-negative myeloproliferative neoplasms (MPNs)...
- Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.A Tefferi
Leukemia 23:1343-5. 2009
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsAnna M Jankowska
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
Blood 113:6403-10. 2009..We then investigated genes in the commonly affected area for mutations. When we sequenced TET2, we found homozygous and hemizygous mutations...
- Mutation in TET2 in myeloid cancersFrancois Delhommeau
INSERM U790, Institut Gustave Roussy, Villejuif, France
N Engl J Med 360:2289-301. 2009..The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. The mechanisms underlying these disorders are not well defined...
- Acquired mutations in TET2 are common in myelodysplastic syndromesSaskia M C Langemeijer
Department of Hematology and Central Hematology Laboratory, Radboud University Nijmegen Medical Centre and Nijmegen Centre for Molecular Life Sciences, Nijmegen, The Netherlands
Nat Genet 41:838-42. 2009..sequencing in 102 individuals with MDS and identified acquired deletions and missense and nonsense mutations in the TET2 gene in 26% of these individuals...
- Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndromeAzim M Mohamedali
Department of Haematological Medicine, King s College London School of Medicine, London, UK
J Clin Oncol 27:4002-6. 2009..We investigated the sequence integrity of 4q24 candidate tumor suppressor gene TET2 in MDS patients with UPD on chromosome 4.
- Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasmsCécile Saint-Martin
Department of Genetics, Assistance Publique Hopitaux de Paris AP HP Groupe Hospitalier Pitié Salpétrière, Universite Pierre et Marie Curie, Paris, France
Blood 114:1628-32. 2009..A putative tumor suppressor gene, TET2, was recently implicated in MPN and myelodysplastic syndromes through the identification of acquired mutations ..
- Mutations of ASXL1 gene in myeloproliferative neoplasms.N Carbuccia
Leukemia 23:2183-6. 2009
- Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.L Couronné
Leukemia 24:201-3. 2010
- TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider
Hematology Department, Hôpital Cochin APHP, Paris, France
Haematologica 94:1676-81. 2009Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 (Ten-Eleven Translocation-2) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including ..
- Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis.Johanna Flach
Haematologica 95:518-9. 2010
- Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemiaHideki Muramatsu
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH 44195, USA
Blood 115:1969-75. 2010..In total, c-Cbl mutations were detected in 5 (10%) of 49 patients. No mutations were identified in Cbl-b and TET2. c-Cbl and RAS pathway mutations were mutually exclusive...
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasmsFranz X Schaub
Department of Biomedicine, Experimental Hematology, University Hospital Basel, Hebelstr 20, 4031 Basel, Switzerland
Blood 115:2003-7. 2010Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and mutations in TET2 precede the acquisition of JAK2-V617F...
- The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutationsKajsa Paulsson
Department of Clinical Genetics, University and Regional Laboratories, Lund University Hospital, Lund University, Lund, Sweden
Hum Mol Genet 19:1507-14. 2010..partial uniparental disomies for 9p (one case) and 4q (two cases) associated with homozygous mutations of JAK2 and TET2, respectively...
- Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsHadrian Szpurka
Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Leuk Res 34:969-73. 2010..Based on the association of TET2/ASXL1 mutations with MDS/MPN we studied molecular pattern of these genes...
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1A Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1128-38. 2010..a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), Casitas B-lineage lymphoma proto-oncogene (CBL), ..
- Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutationsFlorence Nguyen-Khac
Hématologie biologique, Hopital Pitie Salpetriere, APHP, Paris, France
Genes Chromosomes Cancer 49:919-27. 2010..JAK2V617F and TET2 mutations were searched for in 40 and 32 patients, respectively. Significantly more -7/del(7q) (P = 0...
- Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann
MLL Munich Leukemia Laboratory, Munchen, Germany
J Clin Oncol 28:3858-65. 2010..Thus far, data on a comprehensive cytogenetic or molecular genetic characterization are limited...
- Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic valueAlexander E Smith
Department of Hematologic Medicine, King s College London School of Medicine, London, United Kingdom
Blood 116:3923-32. 2010Mutations in the TET2 gene are frequent in myeloid disease, although their biologic and prognostic significance remains unclear...
- ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer
Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee Aix Marseille II, Marseille, France
Br J Haematol 151:365-75. 2010..and sequencing of 13 candidate genes including ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, PTPN11, RUNX1, TET2 and WT1...
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Myunggon Ko
Department of Pathology, Harvard Medical School, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
Nature 468:839-43. 2010b>TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA...
- Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa
Weill Cornell Medical College, New York, NY 10065, USA
Cancer Cell 18:553-67. 2010..In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants...
- Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenasesWei Xu
State Key Laboratory of Genetic Engineering, School of Life Sciences, Shanghai Medical School, Fudan University, Shanghai 20032, China
Cancer Cell 19:17-30. 2011..Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations...
- Genetics of the myeloproliferative neoplasmsOmar Abdel-Wahab
Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Curr Opin Hematol 18:117-23. 2011..The purpose of this review is to outline the most recent discoveries of the genetic alterations found in patients with MPNs...
- TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutationsYoung Ho Kim
International Agency for Research on Cancer, Lyon, France
J Clin Pathol 64:850-2. 2011Miscoding mutations of the TET2 gene, which encodes the α-ketoglutarate-dependent enzyme that catalyses the conversion of 5-methylcytosine to 5-hydroxymethylcytosine, thus producing DNA demethylation, have been detected in 10-25% of ..
- Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformationKelly Moran-Crusio
Department of Pathology, NYU Cancer Institute, New York University School of Medicine, NY 10016, USA
Cancer Cell 20:11-24. 2011Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies...
- TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesisCyril Quivoron
INSERM, U, Villejuif, France
Cancer Cell 20:25-38. 2011..We report that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a ..
- Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann
MLL Munich Leukemia Laboratory, Munich, Germany
Leukemia 26:934-42. 2012We investigated ten-eleven translocation 2 (TET2) mutations in acute myeloid leukemia (AML), their correlation with other gene mutations and prognostic value. By deep-sequencing, 131 somatic TET2 mutations were identified in 87/318 (27...
- Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosisFabiola Traina
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America
PLoS ONE 7:e43090. 2012..areas of loss of heterozygosity and bidirectional sequencing was performed to evaluate the mutational status of TET2, DNMT3A, ASXL1, EZH2, IDH1/IDH2 and the CBL gene family...
- In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cellsErinn Soucie
Inserm U1068, Centre de Recherche en Cancerologie de Marseille, centre de référence des mastocytoses, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
Blood 120:4846-9. 2012..number of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic KITD816V, TET2 mutation statistically associates with aggressive forms of the disease...
- TET2 promotes histone O-GlcNAcylation during gene transcriptionQiang Chen
Division of Molecular Medicine and Genetics, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
Nature 493:561-4. 2013Ten eleven translocation (TET) enzymes, including TET1, TET2 and TET3, convert 5-methylcytosine to 5-hydroxymethylcytosine and regulate gene transcription...
- TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASSRachel Deplus
Laboratory of Cancer Epigenetics, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
EMBO J 32:645-55. 2013..has linked TET1 function to epigenetic repression complexes, yet mechanistic information, especially for the TET2 and TET3 proteins, remains limited...
- Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphomaFazila Asmar
Haematologica 98:1912-20. 2013..Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigations have shown TET2 mutations in diffuse ..
- Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidationLulu Hu
Fudan University Shanghai Cancer Center, Department of Oncology and Institute of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai 200032, China State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China
Cell 155:1545-55. 2013..Mutations of TET2 are frequently observed in myeloid malignance...
- Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked β-N-acetylglucosamine transferase (OGT)Qiao Zhang
From the Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and
J Biol Chem 289:5986-96. 2014..Although TET1 and TET2 also interact with and can be O-GlcNAcylated by OGT, neither their subcellular localization nor their enzymatic ..
- TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cellsThierry Langlois
Institut National de la Sante et de la Recherche Medicale, UMR 1009, Laboratory of Excellence GR Ex, 114 rue Edouard Vaillant, Villejuif, Paris, France Institut Gustave Roussy, Villejuif, Paris, France Université Paris Sud 11, Orsay, France
Stem Cells 32:2084-97. 2014Ten-eleven-translocation 2 (TET2) belongs to the TET protein family that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine and plays a central role in normal and malignant adult hematopoiesis...
- Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlatesA Tefferi
Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 23:900-4. 2009TET2 (TET oncogene family member 2) is a candidate tumor suppressor gene located at chromosome 4q24, and was recently reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms...
- TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider
Assistance Publique Hopitaux de Paris AP HP, Service d Hematologie Biologique, Hôpital Cochin Hôtel Dieu, Paris, France
Blood 114:3285-91. 2009..of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS...
- Myeloproliferative neoplasms: contemporary diagnosis using histology and geneticsAyalew Tefferi
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Nat Rev Clin Oncol 6:627-37. 2009..Additional MPN-associated molecular markers include mutations of JAK2, MPL, TET2 and KIT...
- [Mutation of tet2 gene and malignant blood disease]Xi Feng Qian
Department of Hematology, Wuxi People Hospital, Nanjing Medical University, Wuxi 214000, Jiangsu Province, China
Zhongguo Shi Yan Xue Ye Xue Za Zhi 18:1096-100. 2010b>Tet2 (the 2nd member of tet oncogene family) is a newly discovered antioncogene on the chromosome 4q24 of the patient with malignant myeloma, which has a potential for functional deletion...
- The molecular pathogenesis of myelodysplastic syndromesMatthew S Davids
Department of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Cancer Biol Ther 10:309-19. 2010..Several genetic abnormalities, including mutations in RUNX1 (AML1), TET2, ASXL1 and TP53, have been discovered in a substantial fraction of MDS cases; genes rearranged or mutated less ..
- Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specificationShinsuke Ito
Howard Hughes Medical Institute
Nature 466:1129-33. 2010..Here we extend this study by demonstrating that all three mouse Tet proteins (Tet1, Tet2 and Tet3) can also catalyse a similar reaction...
- Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemiasOmar Abdel-Wahab
Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer Res 70:447-52. 2010..Frequent mutations were identified in TET2 (26.3%), ASXL1 (19.3%), IDH1 (9.5%), and JAK2 (36...
- Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasmsC S Chim
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
J Clin Pathol 63:942-6. 2010A loss-of-function mutation of TET2, CBL and CEBPA has been implicated in the pathogenesis or leukaemic transformation of myeloproliferative neoplasm...
- Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasmPhilip A Beer
Department of Haematology, Cambridge Institute for Medical Research, Cambridge, UK
Blood 115:2891-900. 2010..A search for additional mutations identified alterations of RUNX1, WT1, TP53, CBL, NRAS, and TET2, without significant differences between JAK2-mutant and wild-type leukemias...
- Significance of JAK2 and TET2 mutations in myelodysplastic syndromesEva Hellstrom-Lindberg
Karolinska Institutet, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
Blood Rev 24:83-90. 2010..The identification of JAK2 and MPL mutations, and more recently TET2, CBL and ASXL-1 mutations in these disorders provide a basis for increased understanding of disease biology and ..
- The lower risk MDS patient at risk of rapid progressionMoshe Mittelman
Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
Leuk Res 34:1551-5. 2010..that methylation of p15 INK4b and of CTNNA1 (in 5q-), high level of methylation of other genes, absence of the TET2 mutation, down regulation of the lymphoid enhancer binding factor 1 (LEF1), mutation of the polycomb-associated ..
- LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutationsA Pardanani
Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 24:1713-8. 2010..LNK mutations were not detected in 78 additional patients with chronic-phase MPN enriched for TET2, IDH, JAK2V617F, or MPL-mutated cases...
- Identification of human candidate genes for male infertility by digital differential displayC Olesen
Department of Medical Genetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, Blegdamsvej 3, DK 2200 Copenhagen N, Denmark
Mol Hum Reprod 7:11-20. 2001..Interestingly, the two tesis expressed-only transcripts, TET1 and TET2, mapped to chromosomal regions where seven and six translocation breakpoints have been reported in infertile males ..
- Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaVéronique Gelsi-Boyer
Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
Br J Haematol 145:788-800. 2009..g. ASXL1, ASXL2, UTX, CXXC4, CXXC5, TET2, TET3). To validate some of these candidates we studied the sequence of ASXL1...
- Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignanciesChristine O'Keefe
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Blood 115:2731-9. 2010..regions and have led to the discovery of tumor suppressor genes, including c-CBL and family members, as well as TET2. Investigations into the underlying mechanisms generating CN-LOH have great promise for elucidating general cancer ..
- JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasmsStephen T Oh
Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2324, Stanford, CA 94305 5821, USA
Expert Rev Hematol 3:323-37. 2010..Mutations in the TET2 gene have been identified in both JAK2 V617F-positive and -negative MPNs and other myeloid neoplasms, but their ..
- Mechanisms of mutations in myeloproliferative neoplasmsRoss L Levine
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Best Pract Res Clin Haematol 22:489-94. 2009..mutation? Single nucleotide polymorphisms at various loci and somatic mutations, such as those in MPLW515L/K, TET2 and in exon 12 of JAK2, may also contribute to the pathogenesis of these MPNs...
- Molecular aspects of myeloproliferative neoplasmsFrancois Delhommeau
INSERM, U1009, Institut Gustave Roussy, Universite Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif, France
Int J Hematol 91:165-73. 2010..There are likely additional somatic genetic factors important for the MPN phenotype like the recently described TET2, ASXL1, and CBL mutations...
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialThorsten Braun
Hopital Avicenne, Assistance Publique Hopitaux de Paris AP HP, Hématologie Clinique, University Paris XIII, Bobigny, France
Blood 118:3824-31. 2011..With a median follow-up of 23 months, overall survival was 48% at 2 years. Mutations in ASXL1, TET2, AML1, NRAS, KRAS, CBL, FLT3, and janus kinase 2 (JAK2) genes, and hypermethylation of the promoter of the tumor ..
- TET2 is essential for survival and hematopoietic stem cell homeostasisK Shide
Department of Gastroenterology and Hematology, Faculty of Medicine, Miyazaki University, Kiyotake, Miyazaki, Japan
Leukemia 26:2216-23. 2012Ten-Eleven-Translocation 2 (TET2) is an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) and thereby alters the epigenetic state of DNA; somatic loss-of-function mutations of TET2 are ..
- SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer
MLL Munich Leukemia Laboratory, Munich, Germany
Blood 120:3080-8. 2012..In addition, ASXL1, CBL, EZH2, JAK2V617F, KRAS, NRAS, RUNX1, and TET2 mutations were investigated in subcohorts...
- Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivoOmar Abdel-Wahab
Human Oncology and Pathogenesis Program, 2 Leukemia Service, 3 Gerstner Sloan Kettering Graduate School of Biomedical Sciences, and 4 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065
J Exp Med 210:2641-59. 2013..Asxl1 deletion reduces hematopoietic stem cell self-renewal, which is restored by concomitant deletion of Tet2, a gene commonly co-mutated with ASXL1 in MDS patients...
- Synergistic mechanisms of DNA demethylation during transition to ground-state pluripotencyJamie A Hackett
Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge CB2 1QN, UK Wellcome Trust MRC Stem Cell Institute, University of Cambridge, Cambridge CB2 1QR, UK Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK
Stem Cell Reports 1:518-31. 2013..Mechanistically, repression of de novo methylases by PRDM14 drives DNA demethylation at slow kinetics, whereas TET1/TET2-mediated 5hmC conversion enhances both the rate and extent of hypomethylation...
- Genetics of myeloproliferative neoplasmsAaron D Viny
From the Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
Cancer J 20:61-5. 2014..Mutations in the de novo DNA methylation protein, DNMT3A, demethylation machinery, TET2 and related IDH1/2 production of oncometabolite 2-hydroxygluterate, and polycomb complex proteins EZH2 and ASXL1 ..
- Somatic mutations and epigenetic abnormalities in myelodysplastic syndromesRaphael Itzykson
Hematology Department, Hopital Saint Louis, Assistance Publique Hopitaux de Paris AP HP, France Université Paris 7, France INSERM Unit U944, Hopital St Louis, Paris, France
Best Pract Res Clin Haematol 26:355-64. 2013..e. cytokine signaling (RAS genes), DNA methylation, (TET2, IDH1/2, DNMT3a genes) histone modifications (ASXL1 and EZH2 genes), and spliceosome (SF3B1 and SRSF2 genes) along ..
- 5-azacytidine improves the osteogenic differentiation potential of aged human adipose-derived mesenchymal stem cells by DNA demethylationXueying Yan
Siegfried Weller Institute for Trauma Research, BG Trauma Center, Eberhard Karls University Tubingen, Tubingen, Germany
PLoS ONE 9:e90846. 2014..activity and matrix mineralization was associated with an increased presence of 5 hmC as well as with an increased TET2 and TET3 gene expression...
- Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogeneticsAntonia Cagnetta
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Hematology and Oncology, I R C C S A O U San Martino IST, Genoa, Italy Electronic address
Leuk Res 38:649-59. 2014..has recently shown the recurrence of genomic aberrations in this category (mutations of FLT3, CEBPA, NPM1, RUNX1, TET2, IDH1/2, DNMT3A, ASXL1, MLL and WT1) thus revealing its marked genomic heterogeneity...
- [Myelodysplastic syndromes]F Thol
Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625, Hannover, Deutschland
Internist (Berl) 56:364-73. 2015..Genes of the splicing machinery as well as genes involved in epigenetic regulation (e.g. ASXL1 and TET2) are most frequently mutated in MDS. Therapy is selected based on the patient risk profile (IPSS)...
- Genetic alterations of DNA methylation machinery in human diseasesTewfik Hamidi
Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, 1808 Park Road 1C, P O Box 389, Smithville, TX 78957, USA
Epigenomics 7:247-65. 2015..DNMT3B) and 'demethylating' proteins, including the ten-eleven translocation (TET) family of dioxygenases (TET1, TET2 and TET3)...
- [TET2 as a gatekeeper for hematologic malignancies]Hideharu Muto
Department of Hematology, Faculty of Medicine, University of Tsukuba
Rinsho Ketsueki 56:651-6. 2015..Most notably, TET2 mutations have frequently been identified in myeloid malignancies, such as myelodysplastic syndromes (MDS), ..
- 5-hydroxymethylation of the EBV genome regulates the latent to lytic switchCoral K Wille
Department of Medical Microbiology and Immunology, Wisconsin Institutes for Medical Research WIMR II, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705
Proc Natl Acad Sci U S A 112:E7257-65. 2015..Decreased 5-hydroxymethylation of cellular and viral genes may contribute to NPC formation. ..
- Vitamin C Facilitates Demethylation of the Foxp3 Enhancer in a Tet-Dependent MannerVarun Sasidharan Nair
Department of Pathology, Hallym University College of Medicine, Chuncheon, Gangwon do 200 702, Korea
J Immunol 196:2119-31. 2016..In this study, we found that vitamin C induces CNS2 demethylation in Tregs in a ten-eleven-translocation 2 (Tet2)-dependent manner...
- Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencingMrinal M Patnaik
Division of Hematology, Mayo Clinic, Rochester, Minnesota
Am J Hematol 91:492-8. 2016..had ≥1 mutations; common mutations being: SF3B1 85%, JAK2V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. In a multivariable survival analysis (n = 82), anemia (P = 0.02) [HB< 10 gm/dl: HR 2.3, 95% CI 1...
- Roles of IDH1/2 and TET2 mutations in myeloid disordersSatoshi Inoue
The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, Ontario Cancer Institute, University Health Network, 610 University Avenue, Toronto, ON, M5G 2M9, Canada
Int J Hematol 103:627-33. 2016..enzymes isocitrate dehydrogenase (IDH) 1 and 2, and the methylcytosine dioxygenase 'ten-eleven translocation 2' (TET2), are common in human myeloid malignancies and drivers of these disorders but the underlying mechanisms remain ..
- Immune Regulator MCPIP1 Modulates TET Expression during Early Neocortical DevelopmentHuihui Jiang
State Key Laboratory of Stem Cells and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
Stem Cell Reports 7:439-53. 2016..MCPIP1 is important for maintenance of the NPC pool. Notably, we demonstrate that MCPIP1 reduces TET (TET1/TET2/TET3) levels and then decreases 5-hydroxymethylcytosine levels...
- DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions.Manuel Buscarlet
Blood 130:753-762. 2017..We report a higher overall prevalence of driver mutations (13.7%), which occurred mostly (93%) in DNMT3A or TET2 and were highly age-correlated. Mutation in these 2 genes had some distinctive effects on end points...
- Identification and characterization of human CXXC10 gene in silicoMasuko Katoh
M and M Medical BioInformatics, Narashino 275 0022, Japan
Int J Oncol 25:1193-9. 2004..CXXC10-2 (937 aa) was homologous to CXXC6, and KIAA1546. Complete coding sequence of KIAA1546 cDNA was determined by assembling BF900449 EST, IMAGE3536481 partial cDNA, ..
- Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker
Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Haematologica 96:1488-95. 2011..To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia...
- TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogeneticsWen Chien Chou
Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
Blood 118:3803-10. 2011The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with primary AML. TET2 mutation occurred in 13...
- [Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance]Yong Min Zhang
Department of Hematology, Nanfang Hospital of Southern Medical Univesity, Guangzhou 510515, China
Zhonghua Xue Ye Xue Za Zhi 33:103-7. 2012To comprehend the abnormalities of JAK2, c-mp, EPOR, MPW515L/K and TET2 genes in patients with familial myeloproliferative neoplasm (MPN) and their relatives, and to explore mechanism of MPN pathogenesis.
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA
Blood 120:4945-51. 2012..6 months for the entire cohort (range, 3-55). TET2/DNMT3A/IDH1/2 mutational status was associated with response in a limited number of patients...
- Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasmJ Menezes
Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre CNIO, Madrid, Spain
Leukemia 28:823-9. 2014..Target sequencing identified 29 recurring genes, ranging in prevalence from 36% for previously known genes, such as TET2, to 12-16% for newly identified genes, such as IKZF3 or ZEB2...
- SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genesKatia Hanssens
Haematologica 99:830-5. 2014..KIT, SRSF2-P95 and TET2 mutations were by far the most frequent, detected in 81%, 24% and 21% of patients, respectively...
- TET2 plays an essential role in erythropoiesis by regulating lineage-specific genes via DNA oxidative demethylation in a zebrafish modelLiang Ge
College of Life Sciences, Zhejiang University, Hangzhou, People s Republic of China Key Laboratory for Cell and Gene Engineering of Zhejiang Province, Hangzhou, People s Republic of China
Mol Cell Biol 34:989-1002. 2014..TETs mediate the conversion of 5mC to hydroxymethylcytosine (5hmC) in zebrafish embryos, and the deletion of TET2 inhibits erythropoiesis by suppressing the expression of the scl, gata-1, and cmyb genes...
- The molecular pathogenesis of the myelodysplastic syndromesAndrea Pellagatti
Leukaemia and Lymphoma Research Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Eur J Haematol 95:3-15. 2015..in genes involved in RNA splicing (including SF3B1, SRSF2, U2AF1, and ZRSR2) and epigenetic modification (including TET2, ASXL1, and DNMT3A)...
- Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiationMaria Armila Ruiz
a Jesse Brown VA Medical Center Chicago, IL, USA
Epigenetics 10:397-407. 2015..The Tet2 and Tet3 dioxygenases that catalyze formation of 5 hmC are expressed during early stages of erythroid ..
- Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell TumorsEleonora Zorzan
Department of Comparative Biomedicine and Food Science, University of Padua, Legnaro, Padua, Italy
PLoS ONE 10:e0142450. 2015..In the present study, the mutational profile of the Tet methylcytosine dioxygenase 2 (TET2), the isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2), the serine/arginine-rich splicing factor 2 (SRSF2), the ..
- Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaM M Patnaik
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Blood Cancer J 6:e385. 2016Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML)...
- Genetic alterations and their clinical implications in older patients with acute myeloid leukemiaC H Tsai
Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Leukemia 30:1485-92. 2016..Compared with the younger patients, the elderly had significantly higher incidences of PTPN11, NPM1, RUNX1, ASXL1, TET2, DNMT3A and TP53 mutations but a lower frequency of WT1 mutations...
- Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome ModulationEsther A Obeng
Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA Division of Hematology Oncology, Department of Medicine, Boston Children s Hospital, Boston, MA 02115, USA Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 30:404-17. 2016..b>Tet2 loss cooperates with Sf3b1(K700E) to cause a more severe erythroid and LT-HSC phenotype...
- The cysteine-rich domain of TET2 binds preferentially to mono- and dimethylated histone H3K36Kazuyuki Yamagata
Division of Newborn Medicine, Children s Hospital Boston
J Biochem . 2017Missense mutations in Ten-eleven translocation 2 (TET2) gene are frequently found in leukaemia patients...
- Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromesXiaoliu Liu
Division of Hematology, Institute of Molecular Hematology, The Second Xiang Ya Hospital, Central South University, Changsha, Hunan, P R of China
Leuk Lymphoma 54:2466-73. 2013The clinical significance and mechanisms of TET2 are not well defined in myeloid malignancies. We detected TET2 mutations and assayed its catalyzing conversion product 5-hydroxymethylcytosine (5-hmC) in 61 Chinese patients with MDS...
- The CpG island methylator phenotype: what's in a name?Laura A E Hughes
Authors Affiliations Departments of Epidemiology and Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht Department of Surgery, Orbis Medical Center, Sittard Geleen Department of Pathology, Leiden University Medical Center, Leiden Department of Neurology, Erasmus University Medical Center, Erasmus University, Rotterdam, the Netherlands Department of Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium and The Johns Hopkins University School of Medicine, Baltimore, Maryland
Cancer Res 73:5858-68. 2013..and IDH2 mutations, and loss-of-function mutations in ten-eleven translocation (TET) methylcytosine dioxygenase-2 (TET2) associated with a hypermethylation phenotype, are also found in multiple enchondromas of patients with Ollier ..
- Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromesMarta Fernandez-Mercado
Haematologica 98:1856-64. 2013..Fifty-two percent of mutations identified were in genes involved in epigenetic regulation (ASXL1, TET2, DNMT3A and JAK2)...
- Comprehensive mutational profiling in advanced systemic mastocytosisJuliana Schwaab
III Medizinische Klinik, Hämatologie und Onkologie, Universitatsmedizin Mannheim, Mannheim, Germany
Blood 122:2460-6. 2013..SF3B1, SETBP1, U2AF1 at mutational hotspot regions, and analyzed complete coding regions of EZH2, ETV6, RUNX1, and TET2. We identified additional molecular aberrations in 24/27 (89%) patients with advanced SM (SM-AHNMD, 5/5; aggressive ..
- The genetic basis of myelodysplasia and its clinical relevanceMario Cazzola
Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy and
Blood 122:4021-34. 2013..Driver mutant genes include those of RNA splicing (SF3B1, SRSF2, U2AF1, and ZRSR2), DNA methylation (TET2, DNMT3A, and IDH1/2), chromatin modification (ASXL1 and EZH2), transcription regulation (RUNX1), DNA repair (TP53), ..
- Focus on the epigenome in the myeloproliferative neoplasmsEunhee Kim
1Human Oncology and Pathogenesis Program and
Hematology Am Soc Hematol Educ Program 2013:538-44. 2013..modifiers have been described in patients with MPNs, including mutations in ASXL1, DNMT3A, EZH2, IDH1, IDH2, and TET2. Moreover, the mutant JAK2 itself has been shown recently to affect histone posttranslational modifications ..
- Feature-based classification of amino acid substitutions outside conserved functional protein domainsBranislava Gemovic
Centre for Multidisciplinary Research and Engineering, Vinca Institute of Nuclear Sciences, University of Belgrade, 12 14 Mihajla Petrovica Alasa, 11001 Belgrade, Serbia
ScientificWorldJournal 2013:948617. 2013..and mutations associated with myeloid malignancies from epigenetic regulators ASXL1, DNMT3A, EZH2, and TET2. PolyPhen-2 and SIFT had significantly lower accuracies in predicting the effects of amino acid substitutions ..
- Probing DNA by 2-OG-dependent dioxygenaseChi Lin Tsai
Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Cell 155:1448-50. 2013..Hu et al. now determine the crystal structure of the TET2 catalytic domain bound to DNA, shedding light on 5mC-DNA substrate recognition and the catalytic mechanism of 5mC ..
- A novel peptide defined through phage display for therapeutic protein and vector neuronal targetingJames K Liu
Department of Neuroscience and Center for Neurological Restoration, NB2 126, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Neurobiol Dis 19:407-18. 2005..Phage ELISAs revealed increases in G(T1b) binding for the Tet1 and Tet2 phage clones when compared to peptideless phage (PLP)...
- Mutations and prognosis in primary myelofibrosisA M Vannucchi
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Leukemia 27:1861-9. 2013..from the European cohort, collected at time of diagnosis, were analyzed for mutations in ASXL1, SRSF2, EZH2, TET2, DNMT3A, CBL, IDH1, IDH2, MPL and JAK2...
- REGULATION AND FUNCTION OF C AB1 NUCLEAR TYROSINE KINASERICHARD VAN ETTEN; Fiscal Year: 2001..Finally, primary abl-/- fibroblasts (before and after rescue with selected abl constructs) will be used to assess the role of c-abl in growth arrest induced by DNA damage. ..
- Chemical modulators of Tet-family proteinsAnjana Rao; Fiscal Year: 2010..We have recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 2-oxoglutarate (2OG)- and Fe(II)-dependent dioxygenases that catalyse ..
- Anjana Rao; Fiscal Year: 2016..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of dioxygenases that utilize molecular oxygen and the cofactors Fe(II) and 2-..
- Merav Socolovsky; Fiscal Year: 2016..following three aims: Aim 1: Determine whether 5mC in erythroid genomic DNA is subject to oxidation by the enzyme Tet2, resulting in replication-dependent, Dnmt1-resistant global demethylation Aim 2: Determine the role of the Cyclin-..
- Anjana Rao; Fiscal Year: 2014..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 2-oxoglutarate (2OG)- and Fe(II)-dependent oxygenases, that convert 5- ..
- Craig B Thompson; Fiscal Year: 2016..R132 or IDH2 R172 versus IDH2 R140 mutations in leukemic prognosis;2) Compare the effects of IDH mutation versus TET2 mutation on histone methylation status and gene expression in AML;3) Determine if the manipulation of 2HG levels ..
- Anjana Rao; Fiscal Year: 2015..We recently discovered that the TET proteins TET1, TET2 and TET3 constitute a new family of 1-ketoglutarate (1KG)- and Fe(II)-dependent dioxygenases that alter DNA ..
- Reuben Kapur; Fiscal Year: 2016..Recent studies in patients with mastocytosis have shown the presence of Tet2 mutations in ~30% patients...
- Gerd P Pfeifer; Fiscal Year: 2016..myelodysplastic syndrome (MDS), because this malignancy often is characterized by mutations in one of the TET genes, TET2. The third Aim will focus on functional studies of TET and TET-associated proteins and their aberrations in cancer.
- Ann Mullally; Fiscal Year: 2015..are to (1) perform detailed functional characterization of Jak2V617F mutant HSCs;(2) investigate the effect of Tet2 loss on Jak2V617F mediated MPN and (3) determine molecular dependencies and co-operating pathways in Jak2V617F ..
- The role of TET oncogene family member 2 in myeloproliferative neoplasmsKristy L Wolniak; Fiscal Year: 2012..Recently, mutations in a previously undefined gene, TET oncogene family member-2 (TET2) has been identified in a subset of patients with MPNs, as well as patients with other diseases of the blood...
- Mingjiang Xu; Fiscal Year: 2016DESCRIPTION (provided by applicant): TET2 gene is mutated and/or deleted with high frequencies in multiple forms of myeloid malignancies including CMML, MDS, MPN and AML...
- Louis C Dore; Fiscal Year: 2015..Additionally, we will identify genome-wide occupancy maps for TET1 and TET2, as well as thymine DNA glycosylase, the enzyme responsible for removing 5fC and 5caC from DNA to allow for ..
- KATHLEEN ANN MARTIN; Fiscal Year: 2016..We have discovered distinct roles for Akt1 and Akt2 in the response to vascular injury. We have also identified TET2 and LMO7 as novel mTORC1-regulated proteins that modulate VSMC phenotype...
- Engineering Tet for single-base resolution sequencing of 5hmCDelin Ren; Fiscal Year: 2013..Professor Chuan He's group at the University of Chicago, we plan to systematically engineer mouse Tet1 and Tet2 to significantly improve the stability and activity of these enzymes for large-scale production and robust ..
- Ross L Levine; Fiscal Year: 2016..Recent studies have identified somatic mutations in known and putative epigenetic modifiers, including TET2, which encodes an enzyme which adds hydroxyl groups to 5-methylcytosine and leads to subsequent DNA hypomethylation...
- High Throughput Screen for JAK2V617F Mutant Selective InhibitorsRoss Levine; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- REGULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE IN KIDNEYBRUCE KONE; Fiscal Year: 2002....
- RASSF1 Tumor Suppressor GeneGERD PFEIFER; Fiscal Year: 2005..The effect of RASSF1 expression on RAS signaling pathways will be studied. We will examine if RASSF1A, alone or in combination with activated RAS, induces cell death (apoptosis). ..
- DNA methylation in cancer genomesGERD PFEIFER; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Regulation of H/K-ATPase in Kidney and ColonBRUCE KONE; Fiscal Year: 2009..abstract_text> ..
- Postdoctoral Training in Renal Diseases and HypertensionBRUCE KONE; Fiscal Year: 2006..It is the goal of the Program that its graduates will contribute to a new generation of academic nephrologists and renal investigators equipped to address the challenging problems in renal diseases and hypertension ..
- UV DAMAGE, REPAIR AND MUTAGENESISGERD PFEIFER; Fiscal Year: 2003..abstract_text> ..
- Characterization of MBD3L1 and MBD3L2GERD PFEIFER; Fiscal Year: 2008..Since both proteins are likely functioning as transcriptional regulators, it will be important to determine if there are changes in gene expression patterns in Mbd311 and Mbd312 (-/-) cells. ..
- GENETIC TARGETING OF HEMATOPOIETIC STEM CELLSTimothy Graubert; Fiscal Year: 2002..The long-term goal of this investigator is to study the molecular bases of hematopoiesis and leukemogenesis as an active member of a clinical Hematology/Bone Marrow Transplant Division. ..
- ACQUISTION OF A CYTOMATION MOFLO CELL SORTERTimothy Graubert; Fiscal Year: 2001..An advisory committee will oversee management of the cell sorter and ensure its long-term stability as a resource for the medical school...
- Acquistion of an inFlux GMP cell sorter.Timothy Graubert; Fiscal Year: 2005..This instrument will provide added value for many funded projects at Washington University that collectively accounted for over $328M in total awards from the NIH in 2002, placing it third among medical centers in the United States. ..
- INHIBITOR OF THE C ABL TYROSINE KINASERICHARD VAN ETTEN; Fiscal Year: 2002..These experiments will yield important new information about the function and regulation of c-Abl and the mode of activation of leukemogenic forms of Abl, and identify new avenues for anti-leukemic therapies. ..
- Novel Cellular Therapies for Ph+ leukemiaRICHARD A contact VAN ETTEN; Fiscal Year: 2010..PHS 398/2590 (Rev. 11/07) Page 2 Continuation Format Page Program Director/Principal Investigator (Last, First, Middle): Van Etten R.A./Klingemann H.K. ..
- Pathogenesis & Therapy of 8p11 Leukemia/LymphomaRICHARD VAN ETTEN; Fiscal Year: 2008..abstract_text> ..